The complaint filed by Robbins LLP centers on the period between February 21, 2025, and May 26, 2026. Plaintiffs allege that Insulet failed to disclose defective manufacturing controls, which created hidden risks for patients relying on the company's insulin delivery technology. According to the filing, these undisclosed procedural failures rendered the firm's public statements materially misleading.

Financial fallout from these disclosures hit shareholders in two distinct waves. On March 12, 2026, the company announced a voluntary Medical Device Correction for specific Omnipod 5 Pods, causing a 6.88% stock decline. A second correction on May 26, 2026, involving Omnipod 5, Omnipod Dash, and Omnipod Eros systems—due to risks of insulin under-delivery—triggered a further 5.07% drop to $146.01 per share. Investors who acquired securities during the class period are now being invited to contact Robbins LLP to participate in the litigation or serve as lead plaintiff.